Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 3
1983 7
1984 7
1985 6
1986 3
1987 9
1988 8
1989 14
1990 11
1991 17
1992 10
1993 12
1994 7
1995 11
1996 11
1997 14
1998 12
1999 18
2000 15
2001 11
2002 18
2003 11
2004 8
2005 16
2006 18
2007 28
2008 28
2009 18
2010 26
2011 26
2012 24
2013 21
2014 26
2015 29
2016 25
2017 28
2018 24
2019 27
2020 27
2021 23
2022 17
2023 14
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

620 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: ribera jm. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Topp MS, et al. Among authors: ribera jm. Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524800 Clinical Trial.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Domínguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bailén R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebrián NM, Martin JLD, Martín A, Barba P. Kwon M, et al. Among authors: ribera jm. Haematologica. 2023 Jan 1;108(1):110-121. doi: 10.3324/haematol.2022.280805. Haematologica. 2023. PMID: 35770532 Free PMC article.
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ribera JM, García-Calduch O, Ribera J, Montesinos P, Cano-Ferri I, Martínez P, Esteve J, Esteban D, García-Fortes M, Alonso N, González-Campos J, Bermúdez A, Torrent A, Genescà E, Mercadal S, Martínez-Lopez J, García-Sanz R. Ribera JM, et al. Blood Adv. 2022 Sep 27;6(18):5395-5402. doi: 10.1182/bloodadvances.2022007764. Blood Adv. 2022. PMID: 35675590 Free PMC article.
[Plasmablastic lymphoma].
Fernández-Álvarez R, Sancho JM, Ribera JM. Fernández-Álvarez R, et al. Among authors: ribera jm. Med Clin (Barc). 2016 Nov 4;147(9):399-404. doi: 10.1016/j.medcli.2016.06.036. Epub 2016 Aug 28. Med Clin (Barc). 2016. PMID: 27576534 Review. Spanish.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM. Jabbour E, et al. Among authors: ribera jm. JAMA. 2024 Jun 4;331(21):1814-1823. doi: 10.1001/jama.2024.4783. JAMA. 2024. PMID: 38722621 Clinical Trial.
JZP458 closes the asparaginase allergy gap.
Ribera JM. Ribera JM. Blood. 2023 Feb 16;141(7):685-686. doi: 10.1182/blood.2022018395. Blood. 2023. PMID: 36795447 Free article. No abstract available.
T-ALL in CNS-3 status needs improvement.
Ribera JM. Ribera JM. Blood. 2023 Apr 13;141(15):1779-1780. doi: 10.1182/blood.2022019532. Blood. 2023. PMID: 37052942 Free article. No abstract available.
620 results